Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6140748 | Virology | 2014 | 9 Pages |
Abstract
Virus-like particles (VLPs) are a promising vaccine platform due to the safety and efficiency. However, it is still unclear whether polyomavirus-based VLPs are useful for this purpose. Here, we attempted to evaluate the potential of polyomavirus VLPs for the antiviral vaccine using simian virus 40 (SV40). We constructed chimeric SV40-VLPs carrying an HLA-Aâ02:01-restricted, cytotoxic T lymphocyte (CTL) epitope derived from influenza A virus. HLA-Aâ02:01-transgenic mice were then immunized with the chimeric SV40-VLPs. The chimeric SV40-VLPs effectively induced influenza-specific CTLs and heterosubtypic protection against influenza A viruses without the need of adjuvants. Because DNase I treatment of the chimeric SV40-VLPs did not disrupt CTL induction, the intrinsic adjuvant property may not result from DNA contaminants in the VLP preparation. In addition, immunization with the chimeric SV40-VLPs generated long-lasting memory CTLs. We here propose that the chimeric SV40-VLPs harboring an epitope may be a promising CTL-based vaccine platform with self-adjuvant properties.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Masaaki Kawano, Katsuma Morikawa, Tatsuya Suda, Naohito Ohno, Sho Matsushita, Toshitaka Akatsuka, Hiroshi Handa, Masanori Matsui,